Cyfuse Biomedical KK (TSE:4892) EPS (Basic): 円-51.52 (TTM As of Dec. 2025)


TSE:4892 Cyfuse Biomedical KK TSE:4892
54 GF Score
Price 円520.00
GF Value 円1,962.33
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Cyfuse Biomedical KK EPS (Basic)?

Cyfuse Biomedical KK TSE:4892 +0.39% 54 EPS (Basic) is 円-51.52 as of Dec. 2025. GuruFocus rates TSE:4892 with a GF Score™ of 54/100 and a GF Value™ of 円1,962.33 (Possible Value Trap). The stock has 5 warning signs investors should review.

Cyfuse Biomedical KK's basic earnings per share (Basic EPS) for the three months ended in Dec. 2025 was 円0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was 円-51.52.

Cyfuse Biomedical KK's EPS (Diluted) for the three months ended in Dec. 2025 was 円0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was 円-51.52.

Cyfuse Biomedical KK's EPS without NRI for the three months ended in Dec. 2025 was 円0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -51.51.

During the past 3 years, the average EPS without NRI Growth Rate was 19.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, Cyfuse Biomedical KK's highest 3-Year average EPS without NRI Growth Rate was 19.60% per year. The lowest was -17.90% per year. And the median was 0.85% per year.

Cyfuse Biomedical KK  (TSE:4892) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Cyfuse Biomedical KK EPS (Basic) Related Terms

Cyfuse Biomedical KK EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Cyfuse Biomedical KK's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyfuse Biomedical KK EPS (Basic) Chart

Cyfuse Biomedical KK Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial 285.52 -177.67 -75.42 -108.34 -86.78

Cyfuse Biomedical KK Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -19.90 -28.96 0.00 -22.56
TSE:4892
54GF Score
Cyfuse Biomedical KK TSE:4892
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cyfuse Biomedical KK EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Cyfuse Biomedical KK's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-763.843-0)/8.802
=-86.78

Cyfuse Biomedical KK's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(0-0)/8.802
=0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-51.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of 円-51.52 mean?
Cyfuse Biomedical KK (TSE:4892) has a EPS (Basic) of 円-51.52 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Cyfuse Biomedical KK and its competitors.
Is Cyfuse Biomedical KK's EPS (Basic) too high?
Cyfuse Biomedical KK's current EPS (Basic) is 円-51.52. Overall, Cyfuse Biomedical KK has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyfuse Biomedical KK's EPS (Basic) compare to ZTS?
Cyfuse Biomedical KK's EPS (Basic) of 円-51.52 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Cyfuse Biomedical KK and its competitors. Cyfuse Biomedical KK's current EPS (Basic) is 円-51.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyfuse Biomedical KK stock overvalued right now?
Based on GuruFocus' analysis, Cyfuse Biomedical KK (TSE:4892) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,962.33, compared to a current price of 円520.00 — trading 73.5% below its estimated fair value. The current EPS (Basic) is 円-51.52. Cyfuse Biomedical KK's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Cyfuse Biomedical KK (TSE:4892), the current EPS (Basic) is 円-51.52 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cyfuse Biomedical KK (TSE:4892) Overvalued in 2026?

Based on GuruFocus' analysis, Cyfuse Biomedical KK stock appears to be undervalued. The current stock price of 円520.00 is trading 73.5% below its estimated GF Value™ of 円1,962.33. GuruFocus considers Cyfuse Biomedical KK to be Possible Value Trap.

Key valuation signals for TSE:4892:

  • EPS (Basic): 円-51.52
  • GF Value™: 円1,962.33 vs. price of 円520.00 (73.5% below fair value)
  • GF Score™: 54/100 with 5 warning signs

No single metric tells the full story. See the TSE:4892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cyfuse Biomedical KK Business Description

Address 3-5-27 Mita, 1st Floor, Sumitomo Real Estate Tokyo Mita South Tower, Minato-ku, Tokyo, JPN, 108-6301
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine-related products. The company focuses on delivering three-dimensional tissues and organs created solely from cells as new 3D cell products to medical fields, including regenerative medicine and drug discovery, through the practical application of three-dimensional cell stacking technology. It is engaged in multifaceted development in the following areas: regenerative medicine, drug discovery support, and the device domain, including the development and sales of 3D cell stacking system equipment, such as bio 3D printers equipped with the company's platform technology.
54GF Score

Get the complete analysis for TSE:4892

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円520.00
Price
円1,962.33
GF Value